Erythromycin Pediatric Dose — Gastrointestinal Motility
Erythromycin is a macrolide antibiotic that also acts as a motilin receptor agonist, promoting coordinated gastric and intestinal smooth muscle contractions. In pediatric practice, low-dose oral erythromycin is used as a prokinetic agent to address gastroparesis, feeding intolerance, and delayed gastric emptying. It is an important option when optimizing enteral nutrition in infants and children who have not responded to conservative measures.
Pediatric Dosing
The recommended prokinetic dose of erythromycin is 15–20 mg/kg/day PO, divided into doses administered every 6–8 hours.
- Daily dose: 15–20 mg/kg/day PO
- Dosing interval: Every 6–8 hours (3–4 divided doses per day)
- Route: Oral (PO)
Worked example: For a 10 kg child using a dose of 15 mg/kg/day divided every 8 hours (3 doses/day): 10 × 15 mg/kg/day = 150 mg/day ÷ 3 doses = 50 mg per dose. At 20 mg/kg/day, the same child would receive 200 mg/day ÷ 3 = approximately 67 mg per dose. Consult institutional protocol for maximum single-dose and duration limits.
Indications and Clinical Context
Erythromycin at sub-antimicrobial prokinetic doses is indicated for pediatric patients experiencing gastroparesis, feeding intolerance, or delayed gastric emptying — conditions frequently encountered in premature neonates, critically ill children in the PICU, and patients with neurological impairment. Its motilin receptor agonist activity accelerates gastric emptying and improves antroduodenal coordination, facilitating advancement of enteral feeds.
This application falls within the gastrointestinal motility category and is considered when standard feeding strategies have been optimized. Duration of therapy should be limited to the shortest effective course given concerns about tachyphylaxis with prolonged use and the potential for development of antimicrobial resistance with ongoing macrolide exposure.
Administration and Monitoring
Erythromycin for prokinesis is administered orally and is typically given 15–30 minutes before feeds or meals to maximize motilin receptor stimulation during the appropriate phase of gut motility. Liquid formulations are available and commonly used in infants and young children. Oral absorption is generally adequate; IV formulations are reserved for situations where enteral access is not feasible — consult institutional protocol for IV prokinetic dosing, as it differs from the oral regimen described here.
- Monitor for: Abdominal cramping, diarrhea, nausea, and vomiting — the most common gastrointestinal adverse effects.
- Cardiac monitoring: Erythromycin can prolong the QTc interval; use with caution in patients on other QT-prolonging agents or with underlying cardiac conditions.
- Drug interactions: Erythromycin is a potent CYP3A4 inhibitor; review concurrent medications carefully.
- Tachyphylaxis: Prokinetic efficacy may diminish with prolonged use; reassess the need for continued therapy regularly.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.